HCW Biologics Inc.
HCWB
$6.02
$0.132.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -78.77% | -63.19% | -9.68% | 22.27% | 2.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -78.77% | -63.19% | -9.68% | 22.27% | 2.82% |
| Cost of Revenue | -75.33% | -60.23% | -29.55% | 3.49% | -11.54% |
| Gross Profit | -86.37% | -70.26% | 71.23% | 96.70% | 60.22% |
| SG&A Expenses | -64.27% | -4.18% | 29.22% | 130.50% | 178.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.06% | -13.78% | 12.21% | 67.34% | 75.84% |
| Operating Income | 58.09% | 6.82% | -14.63% | -73.59% | -90.08% |
| Income Before Tax | 70.29% | 9.63% | -20.12% | -89.19% | -105.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 70.29% | 9.63% | -20.12% | -89.19% | -105.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.29% | 9.63% | -20.12% | -89.19% | -105.09% |
| EBIT | 58.09% | 6.82% | -14.63% | -73.59% | -90.08% |
| EBITDA | 61.22% | 8.14% | -15.11% | -78.43% | -94.09% |
| EPS Basic | 61.32% | 15.71% | -13.26% | -82.72% | -99.19% |
| Normalized Basic EPS | 64.24% | 10.26% | -12.23% | -74.88% | -90.77% |
| EPS Diluted | 61.32% | 15.71% | -13.26% | -81.15% | -97.09% |
| Normalized Diluted EPS | 64.24% | 10.26% | -12.23% | -74.88% | -90.77% |
| Average Basic Shares Outstanding | 33.36% | 12.11% | 7.97% | 3.68% | 2.43% |
| Average Diluted Shares Outstanding | 33.36% | 12.11% | 7.97% | 3.68% | 2.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |